The in vivo CRO market involves contract research organizations that help pharmaceutical and biotechnology companies to conduct research and development activities related to preclinical tests using live animals and humans. In vivo CRO services find wide applications in testing new drugs for toxicity, safety and efficacy before being tested on humans. These CROs aid in reducing costs and risks associated with in-house preclinical research. They offer services ranging from experimental design, animal housing and care, surgical procedures, data analysis and report preparation.
The Global In vivo CRO Market is estimated to be valued at US$ 4.70 billion in 2024 and is expected to exhibit a CAGR of 8.5% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the in vivo CRO market are IQVIA Inc., Crown Bioscience, Taconic Biosciences, Inc., PsychoGenics Inc., Evotec, Janvier Labs, Biocytogen Boston Corp, GemPharmatech, Charles River Laboratories, Icon Plc, Labcorp Drug Development, Parexel International Corporation, SMO Clinical Research (I) Pvt Ltd., WuXi AppTec, ICON plc, and Syneos Health.
In Vivo CRO Market Demand in pharmaceutical industry coupled with rising drug discovery & development activities is fueling the demand for in vivo CRO services. Moreover, increasing stringent regulations for chemical and medical testing have propelled the need for outsourcing preclinical research to specialized CROs.
Advances in 3D organ chips, microphysiological systems, humanized mouse models, and imaging techniques are allowing CROs to offer enhanced predictive translational research services to drug developers. This is helping to accelerate drug development process and lower costs associated with clinical failures.
Market Trends
Rise of regenerative medicine: Growing demand for humanized animal models and organ-on-chip models for transplantation and regenerative medicine research is emerging as a key trend. This is expected to drive greater outsourcing to CROs with relevant expertise.
Focus on specialty areas: In vivo CROs are increasingly focusing on specialized services for areas such as oncology, immunology, CNS disorders, and rare and orphan diseases to aid complex drug development programs. This allows pharmaceutical companies to leverage expert insights.
Market Opportunities
Drug discovery for neurological disorders: Growing incidence of Alzheimer's, Parkinson's, epilepsy and other CNS diseases has opened up significant opportunities for CROs having depth in behavioral assays, imaging, and brain microdialysis capabilities.
Stem cell-derived models: Advancements in stem cell differentiation protocols for generating human tissues and disease-relevant cells types provide opportunities for CROs to develop predictive humanized disease models and assays. This can improve clinical translation.
Impact Of COVID-19 On In Vivo CRO Market:
The COVID-19 pandemic has severely impacted the in vivo CRO market. Countries across the globe went into lockdown to curb the spread of the virus which disrupted various business operations. Research activities involving animals came to a halt as lab facilities were shut down and researchers were restricted from accessing labs. This led to cancellation and delays of several pre-clinical and clinical studies which were in progress. The restrictions also made it difficult to source and transport test animals as well as technicians for in vivo studies. All of these factors negatively impacted the growth of the in vivo CRO market in 2020.
However, with mass vaccination drives and reduction in daily COVID cases globally, research activities are slowly recovering from 2021. Many countries have eased lockdown restrictions and allowed researchers to access lab facilities with proper safety protocols. This is helping projects and studies to resume and the delayed projects to catch up. The demand for CRO services is also picking up as pharmaceutical companies aim to accelerate drug development pipelines that were disrupted during the peak of the pandemic. CROs are adopting digital and remote technologies to ensure continuity of operations while maintaining safety standards. With the pandemic situation expected to be under control in 2022-23, the in vivo CRO market is projected to bounce back and regain its pre-COVID growth rates.
In terms of value, North America is currently the largest market for in vivo CRO globally mainly due to presence of many prominent pharmaceutical companies and biotech firms. It accounts for around 35% share of the total market. Europe holds the second position as a major region with around 30% share. Asia Pacific region is considered the fastest growing market for in vivo CRO globally due to low-cost operations and increasing research spending. The region is expected to witness around 10% CAGR during the forecast period backed by strong growth in countries like China & India.
Get more insights on, In Vivo CRO Market
Get This Report in Japanese Language:
Get This Report in Korean Language:
Explore More Related Article On- Antidepressant Market
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment